Sequella, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sequella.com
Clinical Trials
7
Active:0
Completed:6
Trial Phases
3 Phases
Phase 1:3
Phase 2:2
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (42.9%)Not Applicable
2 (28.6%)Phase 2
2 (28.6%)Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01585636
- Locations
- 🇺🇸
Quintiles Phaes 1 Clinical Study Unit, Lenexa, Kansas, United States
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Sequella, Inc.
- Registration Number
- NCT01252108
PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT01225640
- Locations
- 🇿🇦
Pfizer Investigational Site, Cape Town, South Africa
Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT00990990
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Sequella, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00871949
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
News
No news found